NCT01281228 - The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Obesity

Interventions

DRUG

exenatide

The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.

DRUG

exenatide + exendin (9-39)

The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.

DRUG

placebo

saline infusion

Trial Locations (1)

1007MB

VU University Medical Center, Amsterdam